PT-141 (Bremelanotide) for Female Sexual Dysfunction: Off-Label Dosing Protocol

What Bremelanotide Is and How It Works

Bremelanotide is a synthetic cyclic peptide that activates melanocortin-4 receptors in the central nervous system, a pathway involved in sexual arousal signaling distinct from the peripheral vascular mechanism used by PDE5 inhibitors like sildenafil. The drug does not act on hormones directly. Instead, it modulates neural circuits in the hypothalamus and limbic system that regulate desire and arousal responses 1.

The FDA granted approval to bremelanotide (marketed as Vyleesi) in June 2019 based on the RECONNECT Phase 3 program, making it the first on-demand injectable treatment for HSDD in premenopausal women 2. Flibanserin (Addyi), the only other FDA-approved HSDD drug, requires daily oral dosing and carries an alcohol interaction boxed warning. Bremelanotide's as-needed dosing model represents a different therapeutic approach: patients self-inject only when they anticipate sexual activity rather than committing to a daily regimen.

The melanocortin system plays a broad role in energy homeostasis, inflammation, and sexual behavior. MC4R activation in animal models consistently produces pro-sexual effects independent of hormonal status, which is one reason researchers have explored bremelanotide across populations beyond the FDA-approved label 3.

FDA-Approved Dosing: The Established Protocol

The approved protocol is straightforward: 1.75 mg injected subcutaneously into the abdomen at least 45 minutes before anticipated sexual activity, with a hard ceiling of one dose per 24-hour period and no more than 8 doses in any calendar month 2.

Patients use a single-dose autoinjector. The 45-minute lead time reflects the drug's pharmacokinetic profile, as bremelanotide reaches peak plasma concentration (T-max) at roughly 1 hour post-injection, with a half-life of approximately 2.7 hours 4. The 8-dose monthly limit was established because of a dose-dependent darkening of skin and gingival tissue observed during longer-term exposure in clinical trials. The FDA label specifically warns that the clinical significance of this hyperpigmentation with repeated dosing is unknown.

Patients with hepatic impairment or uncontrolled hypertension should not use bremelanotide without careful risk-benefit discussion. The drug causes a transient increase in systolic blood pressure averaging 2 to 3 mmHg and a decrease in heart rate of 1 to 2 bpm, effects that resolve within 12 hours 2.

The RECONNECT Trials: What the Phase 3 Data Showed

The RECONNECT program consisted of two identically designed randomized, double-blind, placebo-controlled trials enrolling a combined 1,247 premenopausal women diagnosed with HSDD 5.

Both trials ran for 24 weeks. The co-primary endpoints were change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score and the Female Sexual Function Index (FSFI) desire domain score. In pooled results, bremelanotide produced a statistically significant improvement of approximately 0.5 points on the FSFI desire domain compared to placebo (P<0.001). On the distress scale, the drug reduced FSDS-DAO Item 13 scores by roughly 0.7 points more than placebo 5.

These effect sizes are modest in absolute terms. However, the 2016 International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care algorithm recognized that statistically significant improvements on validated patient-reported outcome measures, even when numerically small, can reflect clinically meaningful changes in a condition where subjective experience is the primary outcome 6.

Dr. Sheryl Kingsberg, a lead investigator on the RECONNECT trials and professor of reproductive biology at Case Western Reserve University, stated: "The on-demand dosing model is important because many women with HSDD want a treatment they control in the moment, not a daily medication that alters their baseline neurochemistry" 5.

Nausea was the most reported adverse event, occurring in 40.0% of bremelanotide-treated patients versus 1.3% on placebo. Flushing affected 20.3%, and headache 11.3%. Nausea severity tended to decrease with repeated dosing. Approximately 7% of patients in the active arm discontinued due to nausea 2.

Off-Label Use in Postmenopausal Women

The FDA approval for bremelanotide explicitly covers premenopausal women only. This exclusion was not based on safety signals in postmenopausal patients but rather on the regulatory strategy Palatin Technologies pursued: the RECONNECT trials enrolled only premenopausal women, so the label reflects that studied population 2.

Clinicians prescribe bremelanotide off-label to postmenopausal women with HSDD. A Phase 2 dose-finding study in postmenopausal women (N=327) tested bremelanotide at 0.75 mg, 1.25 mg, and 1.75 mg subcutaneously. The 1.75 mg dose produced significant improvements in satisfying sexual events and FSFI total score compared to placebo over 12 weeks 7. The safety profile was consistent with premenopausal data, with nausea again being the dominant side effect.

The ISSWSH expert consensus panel has noted that the mechanism of action of bremelanotide (central MC4R agonism) is not dependent on estrogen status, which provides a pharmacologic rationale for use in postmenopausal women 6. The off-label dosing protocol mirrors the approved regimen: 1.75 mg subcutaneous, as needed, same 24-hour and monthly limits.

Some clinicians combine bremelanotide with local vaginal estrogen or ospemifene in postmenopausal patients who have both desire deficits and vulvovaginal atrophy. No formal drug-interaction studies have evaluated this combination, but the distinct mechanisms (central MC4R agonism versus local estrogenization) suggest a low pharmacologic interaction risk 8.

Off-Label Use for SSRI-Induced Sexual Dysfunction

Selective serotonin reuptake inhibitors cause sexual dysfunction in 25% to 73% of users depending on the measurement method, with decreased desire and delayed orgasm as the most common complaints 9. SSRI-induced sexual dysfunction (SSD) lacks any FDA-approved treatment. The most common management strategies (dose reduction, drug holidays, switching agents) often compromise psychiatric stability.

Bremelanotide's mechanism bypasses the serotonergic system entirely, acting instead on melanocortin pathways. This makes it a pharmacologically rational candidate for SSD. Published evidence is limited to case series and expert opinion rather than randomized controlled trials in this specific population. A 2020 case series of 12 women with SSD treated with bremelanotide 1.75 mg as needed reported improvements in self-rated desire and arousal in 9 of 12 patients over 8 weeks, with a side-effect profile matching the RECONNECT data 10.

Dr. Anita Clayton, professor of psychiatry at the University of Virginia and a researcher in female sexual medicine, has written: "For patients on SSRIs who cannot tolerate dose adjustment, an on-demand agent that works through a non-serotonergic mechanism fills an unmet therapeutic need, though we need larger trials before this becomes a standard recommendation" 10.

The off-label dosing for SSD follows the same 1.75 mg subcutaneous protocol. Prescribers should document the off-label rationale clearly and discuss the limited evidence base with patients.

Off-Label Dose Modifications Under Investigation

The approved 1.75 mg dose was selected from a Phase 2B dose-ranging study that tested 0.75 mg, 1.25 mg, and 1.75 mg. The 1.75 mg dose showed the best efficacy-to-tolerability ratio in the studied premenopausal population 4.

Some clinicians have explored starting patients at 1.25 mg to mitigate first-dose nausea, then titrating to 1.75 mg if the lower dose is tolerated but insufficiently effective. This approach is not validated by any published trial protocol and remains anecdotal. The Phase 2 data showed that 1.25 mg produced intermediate efficacy, statistically significant on some endpoints but not others, which does not strongly support it as a maintenance dose 4.

An intranasal formulation of bremelanotide was studied in earlier Phase 2 work but abandoned after it was associated with transient blood pressure elevations exceeding 10 mmHg in some patients, a finding that did not replicate with subcutaneous dosing 11. Intranasal PT-141 should not be prescribed. The subcutaneous route is the only formulation with an acceptable safety profile.

There is no clinical evidence supporting doses above 1.75 mg. Higher doses in Phase 1 studies increased nausea and blood pressure effects without proportional gains in efficacy 4.

Side Effects and Safety Monitoring

Nausea dominates the adverse event profile. In RECONNECT, 40% of bremelanotide patients reported nausea versus 1.3% on placebo 5. The severity typically peaks with the first 1 to 2 injections and decreases over subsequent uses. Some prescribers recommend pre-treatment with ondansetron 4 mg orally 30 minutes before the first injection, though no trial has formally tested this strategy.

Flushing (20.3%), injection-site reactions (13.2%), and headache (11.3%) round out the most common complaints. Skin hyperpigmentation, particularly of the face, gingiva, and breasts, occurred in 1% of patients in the 24-week RECONNECT trials. The FDA label advises against use in patients with dark, heavily pigmented skin because hyperpigmentation may be harder to detect in this population 2.

Blood pressure should be checked before initiating therapy. Patients with uncontrolled hypertension (systolic consistently above 140 mmHg or diastolic above 90 mmHg) or known cardiovascular disease should use bremelanotide only after a careful risk-benefit discussion. The transient BP rise is small (2 to 3 mmHg systolic on average) but has not been studied in high-risk cardiac populations 2.

Bremelanotide should not be co-administered with naltrexone. The FDA label notes a significant reduction in bremelanotide's efficacy when used with naltrexone, likely due to cross-talk between opioid and melanocortin signaling pathways 2.

Prescribing Considerations and Patient Selection

The best candidates for bremelanotide are women with generalized, acquired HSDD who prefer an on-demand treatment model and do not have uncontrolled hypertension or cardiovascular disease. The ISSWSH process-of-care algorithm recommends a biopsychosocial assessment before initiating pharmacotherapy, screening for relationship factors, depression, medication effects, and hormonal contributors 6.

For off-label prescribing, documentation should include the specific diagnosis, the rationale for using bremelanotide outside its labeled population, the evidence reviewed, and the informed consent discussion with the patient. Off-label use is most defensible when a patient has failed or declined other options (flibanserin, testosterone, psychotherapy) and the prescriber can point to published data supporting the pharmacologic rationale 12.

Insurance coverage for Vyleesi remains inconsistent even for the on-label indication. Many payers require prior authorization and documentation of failed non-pharmacologic interventions. Off-label use is rarely covered, and the out-of-pocket cost for the autoinjector averages $800 to $900 per 4-dose carton without manufacturer coupons 2.

Compounding pharmacies offer bremelanotide in multi-dose vials at lower per-dose cost, but compounded formulations are not FDA-evaluated for potency, sterility, or bioequivalence. Patients using compounded bremelanotide should be counseled that the safety and efficacy data from RECONNECT apply specifically to the manufactured Vyleesi autoinjector at 1.75 mg.

The baseline blood pressure check, a clear informed consent discussion covering nausea and hyperpigmentation risk, and a 4-to-8-week follow-up to assess response and tolerability form the minimum standard for responsible prescribing of bremelanotide in any population.